Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OPSSF Opsens Inc (QX)

0.00 (0.00%)
Feb 29 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0.00
Bid Price 2.12
Ask Price 2.35
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Opsens Inc (QX) OPSSF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 2.13893 19:00:00
Open Price Low Price High Price Close Price Prev Close
2.13893 2.13893
Trades Volume Avg Volume 52 Week Range
0 0.00 - 0.97 - 2.14
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.13893 USD

Opsens Inc (QX) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 246.70M 115.34M 103.00M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Opsens (QX) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OPSSF Message Board. Create One! See More Posts on OPSSF Message Board See More Message Board Posts

Historical OPSSF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months2.1252.13892.122.1330,8680.013930.66%
6 Months1.4452.141.182.0685,5410.6939348.02%
1 Year1.3352.140.971.8144,2880.8039360.22%
3 Years1.29792.990.971.8643,7930.8410364.80%
5 Years0.583312.990.29451.6837,1461.56266.69%

Opsens (QX) Description

OpSens focuses mainly on cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of more than 200,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, the United Kingdom, Japan, and Canada. OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

Your Recent History

Delayed Upgrade Clock